Pursuing Lung Cancer Precision Medicine, with Jonathan Spicer, MD, PhD


The prominent clinical investigator joins to discuss adjuvant and neoadjuvant care research, as well as the application of biomarkers in personalized care.

Episode Highlights

0:15 Intro
3:09 Low-dose CT screening uptake in Canada
4:45 Evolution of adjuvant, neoadjuvant therapies
7:10 Reviewing CheckMate 816
10:56 Reviewing KEYNOTE-671
12:58 The impact of neoadjuvants on operability
16:15 Treatment-specific biomarkers for lung cancer
21:13 The short-term future of lung cancer therapy
24:31 Outro

As lung cancer prevalence and mortality continues to burden an aging North American population, the strategies to apply the right care to the right patient at the right time is becoming increasingly refined. Precision medicine, a catch-all term for the pursuit of clinical and demographic-tailored treatment, is becoming a more tangible pursuit as researchers uncover intricate details on their care regimens over time.

In later-stage lung cancer, understanding the utility of neoadjuvant, perioperative and adjuvant therapy relevant to invasive care in the right patient could make all the difference.

In the latest episode of Lungcast, an increasingly recognized investigator in the field of lung cancer intervention discusses his contributions to our understanding of treatment timing. He additionally helps project outlook on the future of biomarker-based care, and precision medicine as a feasible strategy in lung cancer care.

Jonathan Spicer, MD, PhD, medical director of the McGill Thoracic Oncology Program and principal investigator at the McGill Thoracic Surgery & Upper Gastrointestinal Cancer Research Laboratories, joins our February 2024 episode of Lungcast to discuss neoadjuvant and adjuvant lung cancer research with Albert Rizzo, MD, chief medical officer of the American Lung Association (ALA).

Lungcast is a monthly respiratory news podcast series hosted by Al Rizzo, MD, chief medical officer of the ALA, and produced by HCPLive.

Throughout the episode, Spicer discusses his involvement in the pivotal CheckMate 816 and KEYNOTE-671 trials. He also reviews the understood safety and efficacy interplay of invasive and perioperative treatment, as well as his outlook on the coming years of lung cancer care capabilities.

Subscribe to Lungcast on Spotify here, or listen to the episode below.

Related Videos
A Promising Pipeline for COPD
Projecting Dupilumab's Fit in COPD
What the Ensifentrine FDA Approval Means for COPD
Pavel Strnad, MD | Credit: RWTH Aachen
Caroline Sisson, MMS, PA-C: Updates in Pulmonary Function Testing
© 2024 MJH Life Sciences

All rights reserved.